A meta-analysis of four major trials found that GLP-1 receptor agonists reduced major cardiovascular events by 10%, cardiovascular death by 13%, and all-cause mortality by 12% in people with type 2 diabetes.
12% reduction in all-cause mortalityGLP-1 receptor agonists significantly reduced death from any cause compared to placebo across four large randomized trials (HR 0.88, p=0.002)
What the researchers found
Across four cardiovascular outcome trials (ELIXA, LEADER, SUSTAIN 6, and EXSCEL), GLP-1 receptor agonists produced a significant 10% relative risk reduction in the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke (HR 0.90, 95% CI 0.82–0.99, p=0.033).
Cardiovascular mortality was reduced by 13% (HR 0.87, 95% CI 0.79–0.96, p=0.007) and all-cause mortality by 12% (HR 0.88, 95% CI 0.81–0.95, p=0.002). No significant effects were found for individual endpoints of heart attack, stroke, unstable angina hospitalization, or heart failure hospitalization when analyzed separately.
Why it matters
This meta-analysis provided some of the first pooled evidence that GLP-1 receptor agonists as a drug class offer cardiovascular protection — not just blood sugar control — for people with type 2 diabetes, a population at high cardiovascular risk. It helped shift clinical thinking about these drugs from glucose-lowering agents to cardioprotective therapies.
How the study worked
This was a systematic review and meta-analysis. Researchers searched PubMed and MEDLINE for randomized controlled trials comparing GLP-1 receptor agonists to placebo in adults with type 2 diabetes, with cardiovascular outcomes as primary endpoints. Four eligible trials were identified. Data were pooled using a random-effects model to calculate overall hazard ratios for cardiovascular outcomes and odds ratios for safety outcomes.
What this study cannot tell us
The meta-analysis included only four trials available at the time, each testing a different GLP-1 receptor agonist with varying trial designs and patient populations. The individual drugs showed varying degrees of benefit, and the analysis could not determine whether cardiovascular protection is a true class effect or driven by specific agents. Between-trial heterogeneity, while low-to-moderate, was present.
How to read the evidence
This is a meta-analysis of four large, randomized, placebo-controlled cardiovascular outcome trials — the highest level of clinical evidence. The included trials (ELIXA, LEADER, SUSTAIN 6, EXSCEL) enrolled thousands of patients with rigorous methodology.
When this study was published
Published in 2018, this was an early and influential meta-analysis. Since then, additional GLP-1 RA cardiovascular outcome trials have been completed, further supporting these findings.
The bigger picture
This meta-analysis was pivotal in establishing GLP-1 receptor agonists as cardiovascular-protective medications, contributing to major guideline changes that now recommend these drugs for type 2 diabetes patients with cardiovascular disease. It also set the stage for investigating cardiovascular benefits of newer agents like tirzepatide and oral semaglutide.
Questions still open
- Is the cardiovascular benefit a true class effect of all GLP-1 receptor agonists, or do specific drugs drive the overall result?
- Would GLP-1 receptor agonists show similar cardiovascular benefits in people without type 2 diabetes?
- What are the mechanisms by which GLP-1 receptor agonists reduce cardiovascular mortality beyond glucose control?
Common questions
Which GLP-1 drugs were included in this meta-analysis?
Did GLP-1 drugs cause more side effects than placebo in these trials?
Read the original research
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
The lancet. Diabetes & endocrinology, 6(2), 105-113
Citation
Bethel, M Angelyn; Patel, Rishi A; Merrill, Peter; Lokhnygina, Yuliya; Buse, John B; Mentz, Robert J; Pagidipati, Neha J; Chan, Juliana C; Gustavson, Stephanie M; Iqbal, Nayyar; Maggioni, Aldo P; Öhman, Peter; Poulter, Neil R; Ramachandran, Ambady; Zinman, Bernard; Hernandez, Adrian F; Holman, Rury R. (2018). Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.. The lancet. Diabetes & endocrinology, 6(2), 105-113. https://doi.org/10.1016/S2213-8587(17)30412-6